Drug Profile
YM 337
Alternative Names: SMART anti-platelet antibodyLatest Information Update: 04 May 2004
Price :
$50
*
At a glance
- Originator PDL BioPharma; Yamanouchi
- Class Antiplatelets; Monoclonal antibodies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis; Stroke; Thrombosis
Most Recent Events
- 04 May 2004 YM 337 is available for licensing (http://www.yamanouchi.com)
- 01 Mar 2004 Discontinued - Phase-II for Coronary artery restenosis in Europe (Injection)
- 01 Mar 2004 Discontinued - Phase-II for Coronary artery restenosis in USA (Injection)